Evidence map›Paper›PMID 37658272›Full record

ArticleAnnals of surgical oncology2023

The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy.

Peter Blumencranz, Mehran Habibi, Steve Shivers, Geza Acs, Lisa E Blumencranz, Erin B Yoder, Bastiaan van der Baan, Andrea R Menicucci, Patricia Dauer, William Audeh and 1 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01501487 (MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01501487 phase4completednot on this map

MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I

TypeinterventionalSponsorAgendiaRan2011 to 2017Enrolled226ConditionsBreast CancerArmsTAC chemotherapy, TC chemotherapy, Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy, TCH chemotherapy, T + trastuzumab followed by CEF + trastuzumab
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Peter BlumencranzBayCare Oncology, Clearwater, FL, USA.
Mehran HabibiJohns Hopkins University, Baltimore, MD, USA.
Steve ShiversComprehensive Breast Cancer Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Geza AcsDepartment of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Lisa E BlumencranzAgendia, Inc., Irvine, CA, USA.
Erin B YoderAgendia, Inc., Irvine, CA, USA.
Bastiaan van der BaanAgendia, NV, Amsterdam, The Netherlands.
Andrea R MenicucciAgendia, Inc., Irvine, CA, USA.
Patricia DauerAgendia, Inc., Irvine, CA, USA.
William AudehAgendia, Inc., Irvine, CA, USA. william.audeh@agendia.com.
Charles E CoxComprehensive Breast Cancer Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeoadjuvant chemotherapy (NCT) increases the feasibility of surgical resection by downstaging large primary breast tumors and nodal involvement, which may result in surgical de-escalation and improved outcomes. This subanalysis from the Multi-Institutional Neo-adjuvant Therapy MammaPrint Project I (MINT) trial evaluated the association between MammaPrint and BluePrint with nodal downstaging. PATIENTS AND

methodsThe prospective MINT trial (NCT01501487) enrolled 387 patients between 2011 and 2016 aged ≥ 18 years with invasive breast cancer (T2-T4). This subanalysis includes 146 patients with stage II-III, lymph node positive, who received NCT. MammaPrint stratifies tumors as having a Low Risk or High Risk of distant metastasis. Together with MammaPrint, BluePrint genomically (g) categorizes tumors as gLuminal A, gLuminal B, gHER2, or gBasal.

resultsOverall, 45.2% (n = 66/146) of patients had complete nodal downstaging, of whom 60.6% (n = 40/66) achieved a pathologic complete response. MammaPrint and combined MammaPrint and BluePrint were significantly associated with nodal downstaging (p = 0.007 and p < 0.001, respectively). A greater proportion of patients with MammaPrint High Risk tumors had nodal downstaging compared with Low Risk (p = 0.007). When classified with MammaPrint and BluePrint, more patients with gLuminal B, gHER2, and gBasal tumors had nodal downstaging compared with HR+HER2-, gLuminal A tumors (p = 0.538, p < 0.001, and p = 0.013, respectively).

conclusionsPatients with genomically High Risk tumors, defined by MammaPrint with or without BluePrint, respond better to NCT and have a higher likelihood of nodal downstaging compared with patients with gLuminal A tumors. These genomic signatures can be used to select node-positive patients who are more likely to have nodal downstaging and avoid invasive surgical procedures.

Indexed as

Breast NeoplasmsBreastChemotherapy, AdjuvantErb-b2 Receptor Tyrosine KinasesFemaleHumansNeoadjuvant TherapyProspective StudiesErb-b2 Receptor Tyrosine Kinases70-gene signature80-gene signatureAxillary stagingNodal downstagingSurgical management

Identifiers

PMID37658272
PMCPMC10625953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.